Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Minimal-change disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    15 result(s) found for: Minimal-change disease. Displaying page 1 of 1.
    EudraCT Number: 2017-001206-16 Sponsor Protocol Number: 121934 Start Date*: 2017-09-15
    Sponsor Name:Aarhus University hospital
    Full Title: Treatment of primary minimal change nephropathy. A randomized, open-labeled, non-inferiotiry study on prednisolone and vitamin D
    Medical condition: Minimal Change Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10027643 Minimal change glomerulonephritis LLT
    21.1 100000004857 10058326 Minimal change disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011170-15 Sponsor Protocol Number: P071226 Start Date*: 2009-08-10
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Evaluation de l'efficacité d'une corticothérapie à faible dose, associée à l'acide mycophénolique (Myfortic) dans le traitement d'attaque du syndrome néphrotique à lésions glomérulaires minimes de ...
    Medical condition: Syndrome néphrotique à lésions glomérulaires minimes (SNLGM).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029168 syndrome néphrotique à lésions glomérulaires minimes PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-006750-17 Sponsor Protocol Number: NEMO Start Date*: 2009-04-14
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: A prospective, sequential study to assess the efficacy of rituximab therapy in maintaining remission of nephrotic syndrome after steroid and immunosuppressive therapy withdrawal in patients with st...
    Medical condition: Nephrotic Syndrome secondary to minimal change disease (MCD) or idiopathic focal and segmental glomerulosclerosis (FSGS.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029171 LLT
    9.1 10058326 LLT
    9.1 10016832 LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000621-27 Sponsor Protocol Number: RTRX-RE021-201 Start Date*: 2022-10-20
    Sponsor Name:Travere Therapeutics, Inc.
    Full Title: A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects with Selected Proteinuric Glomerular Diseases (E...
    Medical condition: Proteinuric glomerular diseases including: •Focal segmental glomerulosclerosis (FSGS) •Minimal change disease (MCD) •Immunoglobulin A nephropathy (IgAN) •Immunoglobulin A vasculitis (IgAV) •Al...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10067757 Focal segmental glomerulosclerosis PT
    20.0 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    22.1 100000004858 10082959 IgA vasculitis LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10001843 Alport's syndrome PT
    21.1 10038359 - Renal and urinary disorders 10058326 Minimal change disease LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) ES (Temporarily Halted) SE (Trial now transitioned) PL (Temporarily Halted) DE (Restarted) IT (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002430-76 Sponsor Protocol Number: 15OKG16 Start Date*: 2016-11-17
    Sponsor Name:Radboudumc, Amalia Children’s Hospital, Department of Pediatrics
    Full Title: Double-blind, randomized, placebo controlled noninferiority intervention study to REduce STEroids in Relapsing Nephrotic syndrome
    Medical condition: Nephrotic syndrome relapse in children
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10029172 Nephrotic syndrome with unspecified pathological lesion in kidney LLT
    20.1 10038359 - Renal and urinary disorders 10029164 Nephrotic syndrome PT
    20.0 10038359 - Renal and urinary disorders 10029168 Nephrotic syndrome with lesion of minimal change glomerulonephritis LLT
    20.0 10038359 - Renal and urinary disorders 10042826 Syndrome nephrotic LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014292-52 Sponsor Protocol Number: GRIM1002 Start Date*: 2009-10-28
    Sponsor Name:Imperial College NHS trust
    Full Title: Tacrolimus vs prednisolone for the treatment of nephrotic syndrome secondary to minimal change disease: A Randomised Control Trial
    Medical condition: Nephrotic syndrome with lesion minimal change glomerulonephritis
    Disease: Version SOC Term Classification Code Term Level
    05 10029167 nephrotic syndrome secondary with lesion of minimal change glomerulonephritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-003366-27 Sponsor Protocol Number: R-SRNS17 Start Date*: 2017-12-21
    Sponsor Name:Radboud University Nijmegen Medical Center
    Full Title: Efficacy of rituximab in comparison to continued corticosteroid treatment in idiopathic nephrotic syndrome unresponsive to 8 weeks of high dose prednisone.
    Medical condition: Idiopathic nephrotic syndrome Focal segmental glomerulosclerosis Minimal change disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-002004-33 Sponsor Protocol Number: FCRD01 Start Date*: 2007-08-15
    Sponsor Name:Encysive Pharmaceuticals Inc
    Full Title: The effects of sitaxsentan once daily dosing on proteinuria, 24 hour systemic blood pressure and arterial stiffness in subjects with chronic kidney disease.
    Medical condition: Chronic Kidney Disease (CKD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000484-23 Sponsor Protocol Number: NEFRTX1 Start Date*: 2020-07-09
    Sponsor Name:Vall d'Hebron Institute of Research
    Full Title: CHARACTERIZATION OF RITUXIMAB PHARMACOKINETICS IN PATIENTS WITH KIDNEY DISEASES WITH PRIMARY GLOMERULAR AFFECTATION
    Medical condition: KIDNEY DISEASES WITH PRIMARY GLOMERULAR AFFECTATION (glomerulonefritis membranosa, glomerulonefritis por cambios mínimos, vasculitis, glomerulosclerosis focal y segmentaria.)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-005450-36 Sponsor Protocol Number: IM101-566 Start Date*: 2016-08-01
    Sponsor Name:Bristol-Myers Squibb Company
    Full Title: A Phase II Randomized, Placebo-Controlled, Double-Blind, Parallel Arms With Switchover, Pilot Study to Evaluate the Efficacy and Safety of Intravenous Abatacept in Treatment Resistant Nephrotic Syn...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2018-004611-50 Sponsor Protocol Number: CCTU0228 Start Date*: 2019-06-14
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of rituximab in treating de novo or relapsing NS in p...
    Medical condition: Minimal Change Disease (MCD) and Focal segmental glomerulosclerosis (FSGS)
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-003198-17 Sponsor Protocol Number: UZB_20160728 Start Date*: 2016-09-29
    Sponsor Name:Universitair Ziekenhuis Brussel Vrije Universiteit Brussel
    Full Title: A Prospective Interventional Pilot Study on the Use of Valproic Acid for Treatment of Idiopathic Nephrotic Syndrome
    Medical condition: Treatment of Idiopathic Nephrotic Syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000569-30 Sponsor Protocol Number: OFA1 Start Date*: 2015-06-16
    Sponsor Name:IRCCS ISTITUTO GIANNINA GASLINI
    Full Title: Ofatumumab in children with steroid- and calcineurin-inhibitor-resistant nephrotic syndrome: a double-blind randomized, controlled, superiority trial
    Medical condition: Steroid- and calcineurin-inhibitor-resistant nephrotic syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004857 10072914 Steroid-resistant nephrotic syndrome LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001212-29 Sponsor Protocol Number: Prot-0824-2019 Start Date*: 2020-08-26
    Sponsor Name:Aarhus University Hospital, Henrik Birn
    Full Title: Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome
    Medical condition: Nephrotic syndrome is defined as severe proteinuria (> 3.5 g / day), edema and hypoalbuminemia. It is conditioned by a defect in the kidney's glomerular filtration barrier, resulting in the loss of...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10029167 Nephrotic syndrome with lesion of membranous glomerulonephritis LLT
    20.0 100000004857 10029165 Nephrotic syndrome in diseases classified elsewhere LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-005108-21 Sponsor Protocol Number: DMB-3115-2 Start Date*: 2021-04-29
    Sponsor Name:Dong-A ST Co. Ltd.
    Full Title: A Randomized, Double-Blind, Multicentric, Parallel Group Therapeutic Equivalence Study Comparing Efficacy, Safety and Immunogenicity of Subcutaneous DMB-3115 and EU Sourced Stelara® in Patients wit...
    Medical condition: Moderate to Severe Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10071117 Plaque psoriasis LLT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) CZ (Completed) BG (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 16:07:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA